The detection rate of methylene blue combined with another tracer in sentinel lymph node biopsy of early-stage breast cancer: a systematic review and network meta-analysis. (2021)

Peer-Reviewed Study · Liu HJ, Sun MS, Liu LY, Yu ZH, Chen XX, Liu Q, Cheng YJ, Xu L et al. · December 2021

Liu HJ et al., 2021-12: Chinese network meta-analysis of 49 studies and 7,498 patients comparing methylene blue alone, methylene blue plus 99mTc-sulphur colloid and methylene blue plus indocyanine green for sentinel lymph node biopsy in early breast cancer.

The meta-analysis included 7,498 patients in 49 studies.

5222-5237

Liu HJ et al., 2021-12: Chinese network meta-analysis of 49 studies and 7,498 patients comparing methylene blue alone, methylene blue plus 99mTc-sulphur colloid and methylene blue plus indocyanine green for sentinel lymph node biopsy in early breast cancer. C2 China. Study type: systematic review with network meta-analysis, 49 studies, 7,498 patients. Databases searched include CNKI and Wanfang. Comparator: the three tracer strategies against each other. Funder: not stated in the record. Conflicts: the record carries an ICMJE disclosure statement (authors HJL, MSS and others completed forms; text truncated in the record). Journal Transl Cancer Res 10(12):5222-5237. Bearing PARTLY: technique-comparison evidence, not evidence that methylene blue treats cancer. Study type: review.